Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Morgan Stanley to Evaluate Buyout Offer for Tongjitang

publication date: Mar 26, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

The offer to take Tongjitang Chinese Medicines (NYSE: TCM) private will be put in the lap of Morgan Stanley to determine whether the offer represents a fair price for the company. A special committee of the Board of Directors, composed of TCM’s two independent directors, appointed Morgan Stanley Asia Limited to be their financial advisor for the transaction. More details...

Stock Symbol: (NYSE: TCM)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors